---
title: Doctors Can Now Start Migraine Patients on the Newer Drugs First
description: US doctors can now start patients on newer CGRP migraine drugs first under the 2026 AAN and AHS guideline, though insurers may still require older drugs first.
author: Dr Marina Nani (Editor-in-Chief)
date: 2026-09-02T10:35:04.488Z
updated: 2026-09-02T10:35:04.496Z
canonical: https://richhealthmagazine.com/article/migraine-prevention-guideline-cgrp-first-line
image: https://cdn.nanimediahouse.com/migraine-prevention-guideline-235633.webp
categories: Everyday Wellness
content_type: News
region: United States
publication: Rich Health Magazine
schema_type: Article
---

People with frequent migraines no longer have to fail an older, cheaper medication before their doctor can offer a newer CGRP drug, under an updated practice guideline issued on August 31 by the American Academy of Neurology and the American Headache Society.

It is the first update to the two groups' migraine prevention guidance since 2012, and it reflects a medicine cabinet that looks very different now. In 2012 the CGRP drugs, a class made specifically to block a protein involved in migraine attacks, did not exist. The new guideline, published in the journals Neurology and Headache and endorsed by the American Academy of Family Physicians, puts those newer drugs on equal footing with long-standing options from the start of treatment, rather than as a fallback after older drugs fail. It draws on a systematic review of 217 studies.

"If one type of medication is not working well, a different type may still be effective," said Rebecca Burch, MD, a guideline author at the University of Vermont. "It is important for clinicians and patients to know that there are many options."

## Four Migraine Days a Month Is the Threshold for Treatment

The guideline recommends preventive medication for adults who have four or more migraine days a month, four or more moderate-to-severe headache days a month, or migraine that interferes with their ability to work or get through daily tasks. It separates chronic migraine, defined as headaches on 15 or more days a month with at least eight showing migraine features, from episodic migraine, which involves fewer days.

Clinicians are told to walk through the strength of the evidence, possible side effects, cost, and the choice between a daily pill and a monthly or quarterly injection, and to weigh how much migraine is affecting the patient's quality of life. Some options do double duty: certain antidepressants and blood-pressure medicines used to prevent migraine can also treat a second condition a patient has. The guideline calls for checking within a set timeframe whether a new medicine is actually working.

## The Newer Drugs Join the Older Ones as First Choices

The newer class includes the CGRP monoclonal antibodies erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality) and eptinezumab (Vyepti), along with the gepants atogepant (Qulipta) and rimegepant (Nurtec). For chronic migraine specifically, onabotulinumtoxinA (Botox) is included. All received the guideline's high-confidence evidence ratings.

The older, established drugs were not downgraded and remain first-line options too: the beta-blockers propranolol and metoprolol, the anticonvulsants topiramate and valproate (divalproex), and the tricyclic antidepressant amitriptyline. All are inexpensive generics, unlike the newer CGRP drugs, which are costly brand-name medicines.

## Your Insurer May Still Make You Try Older Drugs First

A guideline is not a coverage policy. STAT News has reported that insurers commonly still require prior authorization and step therapy for CGRP drugs, meaning a patient has to try and fail one or more of the older, cheaper generics before a plan will pay for the newer medication, whatever the new first-line guidance says.

STAT News quoted migraine specialist Dr. Andrew Charles, who said guidelines like this one can, in practice, "provide an opportunity for the payers to decline coverage" rather than automatically open the door to newer drugs. The CGRP drugs are expensive brand-name medicines and the older options are cheap generics, which is the reason insurers have leaned on step therapy to control costs. So the guideline dropping the fail-first requirement does not mean your plan will drop it too.

## Fewer People Stop the Newer Drugs, but the Long-Term Data Is Limited

Fewer patients stop the newer CGRP drugs because of side effects than stop the older preventive medicines, though the most commonly reported problems include injection-site reactions, constipation and upper-respiratory infections. Long-term real-world safety data beyond a few years is still limited, and there are no head-to-head trials comparing one CGRP antibody directly against another.

Tamara Pringsheim, MD, a guideline author at the University of Calgary, framed the update as a tool for that conversation. "For people experiencing frequent migraine attacks or attacks that affect the ability to function normally, this guideline can help clinicians determine which preventive medications may be able to help," she said.

For anyone with frequent migraines, that means a conversation to have twice: once with your doctor about whether a CGRP drug or gepant fits your case under the new first-line guidance, and once with your insurer about what your specific plan will actually cover before you count on getting it.

More on migraine and brain health is available from the American Academy of Neurology at [BrainHealth.com](https://brainhealth.com).

## FAQ

**Q: How do you and your doctor choose which migraine prevention medication to try?**
The guideline does not name a single best drug. It tells clinicians to weigh the strength of the evidence, possible side effects, cost, whether a daily pill or a periodic injection suits you better, and whether one medicine could also treat another condition you have, such as high blood pressure. Because there are no trials comparing the newer drugs directly against each other, the choice is an individual one.

**Q: What is the difference between acute and preventive migraine medication?**
This guideline covers preventive medication, taken regularly to reduce how often migraines happen, as distinct from acute medication, taken to treat an attack once it has started.

**Q: Are the newer CGRP migraine drugs better than the older ones?**
The guideline gives both the newer CGRP drugs and gepants and the older established drugs, such as propranolol, topiramate and amitriptyline, its high-confidence evidence ratings. Fewer patients stop the newer drugs because of side effects, but long-term safety data beyond a few years is still limited and there are no trials comparing the CGRP drugs directly against each other.

**Q: Will insurance cover a CGRP drug as a first option?**
Not necessarily. STAT News has reported that insurers commonly still require prior authorization or step therapy, so a patient may have to try an older, cheaper drug first even though the guideline no longer requires that.